Sage Journals: Discover world-class research

Abstract

In this randomized, double-blind study, 126 mild to moderate essential hypertensive patients from northern China were studied to determine the efficacy and safety of a combination therapy of valsartan and hydrochlorothiazide. Patients were randomized to the V80/H12.5 (80 mg valsartan/12.5 mg hydrochlorothiazide) group or the V80 (80 mg valsartan) group. Six weeks after treatment, the mean decrease from baseline in mean sitting systolic blood pressure (MSSBP) was significantly higher in the V80/H12.5 group than the V80 group, but there was no difference in the change of mean sitting diastolic blood pressure (MSDBP) in the two groups. Overall, 80.33% and 70.97% had a controlled response (normalized MSDBP), and 85.25% and 77.42% had a diastolic response (normalized MSDBP or > 10 mmHg reduction in MSDBP) in the V80/H12.5 and V80 groups, respectively (not significantly different). The incidence of adverse events was also similar between the two groups. The combination of 80 mg valsartan/12.5 mg hydrochlorothiazide was efficacious and well tolerated in mild and moderate essential hypertensive patients.

Keywords

Valsartan Angiotensin II receptor blocker Hydrochlorothiazide Hypertension

References

Liu

: Cardiovascular diseases in China. Biochem Cell Biol 2007; 85: 157–163.

: Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124–1134.

Wang

Zhao

: Trends in prevalence, awareness, treatment and control of hypertension in the middle-aged population of China, 1992–1998. Hypertens Res 2004; 27: 703–709.

Neutel

: The use of combination drug therapy in the treatment of hypertension. Prog Cardiovasc Nurs 2002; 17: 81–88.

Burnier

Santschi

Favrat

: Monitoring compliance in resistant hypertension: An important step in patient management. J Hypertens 2003; 21 (suppl): S37–S42.

Lacourcière

Poirier

Hebert

: Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: An 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27: 1013–1021.

Pool

Glazer

Weinberger

: Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007; 29: 61–73.

Philipp

Smith

Glazer

: Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563–580.

European Society of Hypertension—European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

10.

Chobanian

Bakris

Black

: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560–2572.

11.

Horan

Lenfant

: Epidemiology of blood pressure and predictors of hypertension. Hypertension 1990; 15 (2 suppl): I20–I24.

12.

Campbell

Burgess

Choi

: Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999; 160 (9 suppl): S1–S6.

13.

Schwartz

Turner

. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4: 151–160.

14.

Giles

: Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich) 2003; 5 (4 suppl 3): 4–11.

15.

Mallion

Carretta

Trenkwakder

: Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl 2003; 1: 36–43.

16.

Saruta

Qgihara

Matsuoka

: Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res 2007; 30: 729–739.

17.

Kaplan

: Angiotensin II receptor antagonists in the treatment of hypertension. Am Fam Physician 1999; 60: 1185–1190.

18.

Carter

Ernst

Cohen

: Hydrochlorothiazide versus chlorthalidone: Evidence supporting their interchangeability. Hypertension 2004; 43: 4–9.

19.

Franklin

: Systolic blood pressure: It's time to take control. Am J Hypertens 2004; 17: 49S–59S.

20.

Mancia

Seravalle

Grassi

: Systolic blood pressure: An underestimated cardiovascular risk factor. J Hypertens 2002; 20 (suppl): S21–S27.

21.

Brownley

Hurwitz

Schneiderman

: Ethnic variations in the pharmacological and nonpharmacological treatment of hypertension: Biopsychosocial perspective. Hum Biol 1999; 71: 607–639.

22.

Marteau

Zaiou

Siest

: Genetic determinants of blood pressure regulation. J Hypertens 2005; 23: 2127–2143.

Randomized,Double-blinded Trial Evaluation of Valsartan/Hydrochlorothiazide Combination Therapy in Mild to Moderate Essential Hypertension in North-east China

Abstract

Keywords

References